Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

15.91 -0.51 (-3.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Sarepta Draws Wall Street Ire After Third Patient Death This Year: Analyst Says ‘Deeply Concerning’ The Incident Wasn’t Reported Earlier
Via Stocktwits
Gapping stocks in Friday's session
Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
Sarepta Therapeutics Crashes 26% After A Third Gene Therapy Patient Dies
The move wiped out all of the gains Sarepta lodged Thursday after announcing its restructuring plans. 
Via Investor's Business Daily
Topics Death Stocks
Netflix, BlackSky Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
Get insights into the top gainers and losers of Friday's pre-market session.
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Sarepta Therapeutics Stock Plunges Over 30% In Friday Pre-Market: What's Going On
Shares of Sarepta Therapeutics (NASDAQ: SRPT) plunged 26.85% in Friday pre-market after a clinical trial participant died following treatment with a gene therapy, marking the third death linked to the... 
Via Benzinga
Topics Death
Why Interactive Brokers Group Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Sarepta Therapeutics' Reorganization Boosts Investor Confidence
Sarepta agrees to FDA's black box warning and announces major restructuring, including job cuts and cost-saving measures to meet 2027 goals. 
Via Benzinga
AAR, Lucid Group, Monarch Casino & Resort And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Assessing Sarepta Therapeutics: Insights From 35 Financial Analysts
 
Via Benzinga
What's going on in today's pre-market session
Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Why Sarepta Therapeutics Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Sarepta To Lay Off 500 Employees After Two Patient Deaths; Shares Catapult
The company is also restructuring with the hopes of saving $400 million in expenses. 
Via Investor's Business Daily
Topics Death Earnings Government
Sarepta Surges After-Hours As It Slashes 500 Jobs Amid FDA Black Box Warning For Gene Therapy — Retail Eyes Rebound
The company also updated investors on its ELEVIDYS gene therapy label, agreed to an FDA-requested black box warning, and outlined plans to resume dosing in non-ambulant patients. 
Via Stocktwits
Topics Death
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Sarepta Therapeutics Stock Is Surging After The Bell: What's Going On?
Via Benzinga
Get insights into the top gainers and losers of Wednesday's after-hours session.
The regular session of the US market on Wednesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
Top 3 Health Care Stocks That Could Blast Off In July
 
Via Benzinga
Palantir Co-Founder Joe Lonsdale Wants A FDA Overhaul With Special Forces-Style AI Team Because China Is Racing To Outpace US In Biotech
Palantir co-founder Joe Lonsdale is calling for a tech-led overhaul of the FDA through a "special forces" AI team to accelerate drug approvals, warning that outdated systems are allowing China to... 
Via Benzinga
Topics Artificial Intelligence
Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit
The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share. 
Via Stocktwits
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
2 Beaten-Down Stocks to Avoid
Via The Motley Fool
Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny
FDA is investigating Sarepta's Elevidys after two deaths from liver failure in non-ambulatory DMD patients, raising safety and regulatory concerns. 
Via Benzinga
Topics Death
Sarepta Therapeutics Is Already Down 84% This Year. And The Other Shoe Just Dropped.
Shares were under pressure again Wednesday, deepening the 84% loss for the year, as the FDA planned the next steps for Elevidys. 
Via Investor's Business Daily
Topics Death
Sarepta Stock Slumps After FDA Opens Probe Into Patient Death, Analyst Sounds Alarm
H.C. Wainwright reiterated a ‘Sell’ rating on Sarepta on Wednesday with a $10 price target. The firm views the FDA as a potential headwind for Sarepta now. 
Via Stocktwits
Topics Artificial Intelligence Death
This Sarepta Therapeutics Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
 
Via Benzinga
Assessing Sarepta Therapeutics: Insights From 38 Financial Analysts
 
Via Benzinga
Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand
Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered revenue prospects. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.